LLY
Institutional researchers are hiding in Eli Lilly to capture the upside of a $1.1 trillion mega-cap without suffering the downside of a crowded AI bubble.
Lifestyle vanity pursuits like weight loss and hair growth ignite consumer biotech, turning Eli Lilly into a decade-long hold as Zepbound hits $4.2 billion.
LLY's brenipatide GLP-1 pipeline spans 7 trials in psychiatry/addiction/asthma — massive TAM expansion not yet priced in
Eli Lilly will conquer the market to become the world's largest company in five years as investors completely miss the massive incoming demand for GLP-3s.
Minervini buys LLY on Triple Barrel buy signal with VCP breakout and 40% earnings growth ahead
Eli Lilly at all-time highs with weight-loss drug Reta as the gold-mine catalyst plus AI and bio tailwinds
LLY surges ~$70 intraday on a risk-off day, proving defensive pharma absorbs capital fleeing tech.
Eli Lilly is spearheading a tangible healthcare boom by rolling out revolutionary GLP drugs and a permanent single-shot cholesterol treatment.
Eli Lilly could be the biggest stock of the year as AI shifts to product makers with private datasets
Eli Lilly's $3.5B domestic manufacturing bet signals massive reinvestment, bullish for LLY
GLP-1 wave intensifies as Lilly's third-gen retatrutide launches into a culture obsessed with health
Healthcare and Eli Lilly are deeply underperforming and starting to outperform as AI accelerates drug discovery and aging research
Lilly's $1T value rests on tirzepatide, but the patent cliff caps it far short of a $100T dream
Eli Lilly is the application-layer winner of AI; doubles and triples ahead as pharma rides recursive self-improvement.
GLP-1 adoption boosts demand for nutrient-dense food; makers like Eli Lilly ride structural eating shift
Chamath counters that the deepest incumbency moat is a regulated drugmaker, since FDA-trial timelines and biologics manufacturing cannot be disrupted by software the way distribution can. 'The regulated pharma company' has no ticker, so the cleanest large-cap expression of that incumbency-moat long is Eli Lilly.
Eli Lilly is the front-runner to become a trillion-dollar company off the legal GLP-1/peptide boom.
Freeberg walks through retatrutide's phase 3 data and argues it becomes Lilly's premium upsell above tirzepatide, the high-margin tier where the real money gets made. The stake is on Lilly's earnings power, not just the drug.
Eli Lilly's anti-amyloid plus tirzepatide franchise: early-intervention data this year could be a major catalyst.
GLP-1 weight loss drugs are a turbo up-only trend forever, demand not peaking
GLP-1 reframed as a longevity drug widens the market far past obesity, and Lilly is the listed winner of that class.
Amazon distributing Lilly's oral GLP-1 pill while compounders get shut down funnels weight-loss demand to the branded maker.
Lilly's oral GLP-1 (non-peptide) just got approved, validating its pipeline as compounders peddle baseless oral tirzepatide.
Eli Lilly's own AI token factory plus DeepMind, NVIDIA, Insilico ties make it a drug-discovery winner
GLP-1 drugs were the first mass longevity/abundance shift; the category keeps compounding
Oz frames the TrumpRX price cut as a volume detonator that pushes GLP-1s from the vain Upper East Side into Medicare ($50 copay), free Medicaid, and rural America, the exact populations where obesity actually lives. Lilly's just-approved oral pill Foundayo is the form factor he says leapfrogs the injection and lets the market scale.
Eli Lilly is a top-5 name as AI drug discovery accelerates and pharma starts a long-term move.
Most-favored-nation pricing forces US GLP-1 prices from $1,300 to ~$149, compressing pharma margins on blockbusters
MFN drug pricing crushes US branded prices but volume access (Ozempic/Mounjaro at $149) and tariff relief reset pharma economics.
Tech-driven cheap healthcare future leans on GLP-1 drugs as the mass-scale tool to cut cost burden